Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis

(2020) Edward Fox et al.   Multiple Sclerosis Journal

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of B cells in Multiple Sclerosis and related disorders

(2020) Giancarlo Comi et al.   ANNALS OF NEUROLOGY

Infusion-related reactions to rituximab: frequency, mechanisms and predictors

(2018) Franciane Paul et al.   Expert Review of Clinical Immunology

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis

(2017) Ralph HB Benedict et al.   Multiple Sclerosis Journal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis

(2017) Ralph HB Benedict et al.   Multiple Sclerosis Journal

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion

(2013) M Le Garff-Tavernier et al.   LEUKEMIA

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

(2013) Jerry S Wolinsky et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

(2010) M Le Garff-Tavernier et al.   LEUKEMIA

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16

(2008) Christophe de Romeuf et al.   BRITISH JOURNAL OF HAEMATOLOGY